A leader from the topical solutions centered CDMO discusses the differences between approaches by the FDA and EMA, and how to deal with them effectively.
Developers of generic drugs administered with topical drug delivery methods benefit from MedPharm’s in-vitro models to safely demonstrate bioequivalence.